PPARG and prostate carcinoma: Evidence suggests that the endogenous PPAR-γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) suppressed proliferation of and androgen signaling by prostate cancer cells [34], [35].